<DOC>
	<DOCNO>NCT02644551</DOCNO>
	<brief_summary>This interventional safety efficacy study CELENT07 use topical treatment onychomycosis toenail ( tinea unguium ) adults 18 year old . This randomized , double-blind , parallel design , placebo active control study patient mild moderate toenail distal lateral subungual onychomycosis ( DLSO ) ( n=120 ) . Subjects randomize ( 1:1:1 ) receive CELENXT07 , placebo CELENXT07 PENLACÂ® , daily 52 week . Efficacy assessment include complete cure , mycologic cure clinical efficacy safety tolerability .</brief_summary>
	<brief_title>The Efficacy CELEXT07 Treatment Toenail Onychomycosis</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Ciclopirox</mesh_term>
	<criteria>Subjects eligible include study meet follow criterion : 1 . Age &gt; 18 . 2 . Clinically diagnosed onychomycosis target nail . 3 . Presence mild moderate onychomycosis , defined 2050 % area target nail clinically affect . 4 . Has positive KOH examination target nail . 5 . Has positive dermatophyte culture target nail . 6 . Written inform consent obtain . 7 . Subject agree follow protocol . Exclusion Criteria Subjects exclude study meet follow criterion : 1 . Presence disease condition might cause nail abnormality may interfere evaluation study drug . 2 . Use systemic antifungal therapy within 4 week prior Screening visit nonresponsive systemic antifungal therapy onychomycosis . 3 . Use prescription overthecounter topical antifungal therapy toenail within 4 week prior Screening visit . 4 . Woman pregnant , nursing infant , plan pregnancy study period . 5 . Inability understand comply instruction study 6 . Patients le age 18 7 . Individuals know allergy/hypersensitivity Thuja occidentalis , Chelidonium majus , Eucalyptus citriodora , Tea tree Thymus vulgaris .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>